161 related articles for article (PubMed ID: 36101517)
1. Weight change with integrase strand transfer inhibitors among virally suppressed Thai people living with HIV.
Han WM; Kerr SJ; Avihingsanon A; Boettiger DC
J Antimicrob Chemother; 2022 Nov; 77(12):3242-3247. PubMed ID: 36101517
[TBL] [Abstract][Full Text] [Related]
2. Weight gain before and after switch from TDF to TAF in a U.S. cohort study.
Mallon PW; Brunet L; Hsu RK; Fusco JS; Mounzer KC; Prajapati G; Beyer AP; Wohlfeiler MB; Fusco GP
J Int AIDS Soc; 2021 Apr; 24(4):e25702. PubMed ID: 33838004
[TBL] [Abstract][Full Text] [Related]
3. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
[TBL] [Abstract][Full Text] [Related]
4. Weight Change When Initiating, Switching to, and Discontinuing Integrase Strand Transfer Inhibitors in People Living with HIV.
Tieosapjaroen W; Chow EPF; Fairley CK; Hoy J; Aguirre I; Ong JJ
AIDS Patient Care STDS; 2023 Mar; 37(3):131-137. PubMed ID: 36809049
[TBL] [Abstract][Full Text] [Related]
5. Comparison of weight gain after antiretroviral switch to integrase strand transfer inhibitor or tenofovir alafenamide-based therapy.
Sjaarda A; Bernstein A; Sparks A; Saber S; Siegel M
Infection; 2022 Apr; 50(2):407-412. PubMed ID: 34449049
[TBL] [Abstract][Full Text] [Related]
6. Contribution of integrase inhibitor use, body mass index, physical activity and caloric intake to weight gain in people living with HIV.
Guaraldi G; Milic J; Bacchi E; Carli F; Menozzi M; Franconi I; Raimondi A; Ciusa G; Masi V; Belli M; Guaraldi S; Aprile E; Mancini M; Mussini C; Lake JE; Erlandson KM
HIV Res Clin Pract; 2022 Nov; 24(1):1-6. PubMed ID: 36883678
[No Abstract] [Full Text] [Related]
7. One in 10 Virally Suppressed Persons With HIV in The Netherlands Experiences ≥10% Weight Gain After Switching to Tenofovir Alafenamide and/or Integrase Strand Transfer Inhibitor.
Verburgh ML; Wit FWNM; Boyd A; Verboeket SO; Reiss P; van der Valk M
Open Forum Infect Dis; 2022 Jul; 9(7):ofac291. PubMed ID: 35873291
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
[TBL] [Abstract][Full Text] [Related]
9. The effect of a treatment switch to integrase Strand transfer inhibitor-based regimens on weight gain and other metabolic syndrome-related conditions.
Maman O; Ahmad WA; Perzon O; Mahlab-Guri K; Elbirt D; Elinav H
BMC Infect Dis; 2024 Feb; 24(1):221. PubMed ID: 38373940
[TBL] [Abstract][Full Text] [Related]
10. Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV.
Kousari AE; Wilson MP; Hawkins KL; Bandali MM; Henao-Martínez AF; Gardner EM; Erlandson KM
HIV Res Clin Pract; 2024 Dec; 25(1):2339576. PubMed ID: 38831550
[TBL] [Abstract][Full Text] [Related]
11. Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women.
Kerchberger AM; Sheth AN; Angert CD; Mehta CC; Summers NA; Ofotokun I; Gustafson D; Weiser SD; Sharma A; Adimora AA; French AL; Augenbraun M; Cocohoba J; Kassaye S; Bolivar H; Govindarajulu U; Konkle-Parker D; Golub ET; Lahiri CD
Clin Infect Dis; 2020 Jul; 71(3):593-600. PubMed ID: 31504324
[TBL] [Abstract][Full Text] [Related]
12. Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants.
Verboeket SO; Boyd A; Wit FW; Verheij E; Schim van der Loeff MF; Kootstra N; van der Valk M; Reiss P;
PLoS One; 2021; 16(5):e0251205. PubMed ID: 33951089
[TBL] [Abstract][Full Text] [Related]
13. Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors.
Donga P; Emond B; Shah A; Bookhart BK; Anderson D; Vermette-Laforme M; Rossi C; Lafeuille MH
J Comp Eff Res; 2023 Jan; 12(1):e220147. PubMed ID: 36445208
[No Abstract] [Full Text] [Related]
14. Energy balance and body composition after switch between integrase strand transfer inhibitors and doravirine among people with HIV.
Erlandson KM; Mohaweche R; Morrow M; Mawhinney S; Khuu V; Boyd M; Balasubramanyam A; Melanson EL; Lake JE
J Antimicrob Chemother; 2024 Jan; 79(1):179-185. PubMed ID: 38000089
[TBL] [Abstract][Full Text] [Related]
15. Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors.
O'Halloran JA; Cooley SA; Strain JF; Boerwinkle A; Paul R; Presti RM; Ances BM
AIDS; 2019 Jul; 33(9):1477-1483. PubMed ID: 31008801
[TBL] [Abstract][Full Text] [Related]
16. Metabolic Changes Associated With the Use of Integrase Strand Transfer Inhibitors Among Virally Controlled Women.
Summers NA; Lahiri CD; Angert CD; Aldredge A; Mehta CC; Ofotokun I; Kerchberger AM; Gustafson D; Weiser SD; Kassaye S; Konkle-Parker D; Sharma A; Adimora AA; Bolivar H; Cocohoba J; French AL; Golub ET; Sheth AN
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):355-362. PubMed ID: 33060420
[TBL] [Abstract][Full Text] [Related]
17. Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens.
Milic J; Renzetti S; Ferrari D; Barbieri S; Menozzi M; Carli F; Dolci G; Ciusa G; Mussini C; Calza S; Guaraldi G
AIDS; 2022 Oct; 36(12):1643-1653. PubMed ID: 35727163
[TBL] [Abstract][Full Text] [Related]
18. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
19. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV.
Lahiri CD; Xu Y; Wang K; Alvarez JA; Sheth AN; O'Halloran J; Spence AB; Tien P; Gustafson DR; Milam J; Fischl MA; Konkle-Parker D; Adimora AA; Sharma A; Weber KM; Ofotokun I; Rubin LH
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):461-467. PubMed ID: 33231474
[TBL] [Abstract][Full Text] [Related]
20. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
